Replaced platelet concentrates containing a new additive solution, M-sol: Safety and efficacy for pediatric patients

Transfusion

Volumn 53, Issue 9, 2013, Pages 2053-2060

  Yanagisawa, Ryu ^a   Shimodaira, Shigetaka ^a   Kojima, Shunsuke ^a   Nakasone, Nobuhiko ^a   Ishikawa, Shinsuke ^a   Momose, Kayo ^a   Honda, Takayuki ^a   Yoshikawa, Kentaro ^a   Saito, Shoji ^a   Tanaka, Miyuki ^a   Nakazawa, Yozo ^a   Sakashita, Kazuo ^a   Shiohara, Masaaki ^a   Akino, Mitsuaki ^a   Hirayama, Junichi ^a   Azuma, Hiroshi ^a   Koike, Kenichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ADDITIVE; M SOL; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLERGIC TRANSFUSION REACTION; ARTICLE; BLEEDING; BLOOD TRANSFUSION REACTION; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; GENETIC DISORDER; HEMATOLOGIC DISEASE; HUMAN; IMMUNE DEFICIENCY; INFANT; MALE; METABOLIC DISORDER; PRESCHOOL CHILD; SAFETY; SCHOOL CHILD; SOLID TUMOR; THROMBOCYTE TRANSFUSION;

ADOLESCENT; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES;

EID: 84883892013     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12025     Document Type: Article

References (36)

1. Heddle NM, Klama LN, Griffith L, Roberts R, Shukla G, Kelton JG,. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993; 33: 794-797.
2. Geiger TL, Howard SC,. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev 2007; 21: 1-12.
3. Chambers LA, Kruskall MS, Pacini DG, Donovan LM,. Febrile reactions after platelet transfusion: the effect of single versus multiple donors. Transfusion 1990; 30: 219-221.
4. Mangano MM, Chambers LA, Kruskall MS,. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions. Am J Clin Pathol 1991; 95: 733-738.
5. Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD, Constantini LA, Patterson B, Roberts RS, Thorpe KE, Levine MN,. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002; 42: 556-566.
6. Shimodaira S, Ishikawa S, Kojima S, Nakasone N, Nakazawa K, Hasegawa Y, Honda T,. A reporting system for blood components in transfusion reactions in a university hospital: the National Hemovigilance System. Vox Sang 2009; 97 (Suppl S1): 164.
7. Vo TD, Cowles J, Heal JM, Blumberg N,. Platelet washing to prevent recurrent febrile reactions to leucocyte-reduced transfusions. Transfus Med 2001; 11: 45-47.
8. Buck SA, Kickler TS, McGuire M, Braine HG, Ness PM,. The utility of platelet washing using an automated procedure for severe platelet allergic reactions. Transfusion 1987; 27: 391-393.
9. Tobian AA, Savage WJ, Tisch DJ, Thoman S, King KE, Ness PM,. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion 2011; 51: 1676-1683.
10. Kelley WE, Edelman BB, Drachenberg CB, Hess JR,. Washing platelets in neutral, calcium-free, Ringer's acetate. Transfusion 2009; 49: 1917-1923.
11. Hirayama J, Azuma H, Fujihara M, Akino M, Homma C, Kato T, Ikeda H,. Comparison between in vitro qualities of platelets washed with commercially available additive solutions and those washed with M-sol. Vox Sang 2010; 99: 131-135.
12. Azuma H, Ikeda H,. Washed/replaced (W/R)-platelets. ISBT Sci Ser 2009; 4: 342-346.
13. The Japan Society of Transfusion Medicine and Cell Therapy. Indication guidance for washed and replaced platelets and their preparation (Version II). 2009. [cited 2012 Oct 30]. Available from: URL: http://www.jstmct.or.jp/jstmct/ Document/Guideline/Ref9-2.pdf
14. The Japan Society of Transfusion Medicine and Cell Therapy. Indication guidance for washed and replaced platelets and their preparation (Version II), Supplement 1. 2009. [cited 2012 Oct 30]. Available from: URL: http://www.jstmct.or.jp/jstmct/Document/Guideline/Ref9-4.pdf
15. Hirayama J, Azuma H, Fujihara M, Homma C, Yamamoto S, Ikeda H,. Storage of platelets in a novel additive solution (M-sol), which is prepared by mixing solutions approved for clinical use that are not especially for platelet storage. Transfusion 2007; 47: 960-965.
16. Azuma H, Hirayama J, Akino M, Miura R, Kiyama Y, Imai K, Kasai M, Koizumi K, Kakinoki Y, Makiguchi Y, Kubo K, Atsuta Y, Fujihara M, Homma C, Yamamoto S, Kato T, Ikeda H,. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 2009; 49: 214-218.
17. The Japan Society of Transfusion Medicine and Cell Therapy. Indication guidance for washed and replaced platelets and their preparation (Version II), Supplement 2. 2009. [cited 2012 Oct 30]. Available from: URL: http://www.jstmct.or.jp/jstmct/Document/Guideline/Ref9-6.pdf
18. The Japan Society of Transfusion Medicine and Cell Therapy. Indication guidance for washed and replaced platelets and their preparation (Version II), Supplement 3. 2009. [cited 2012 Oct 30]. Available from: URL: http://www.jstmct.or.jp/jstmct/Document/Guideline/Ref9-8.pdf
19. The National Healthcare Safety Network (NHSN). The National Healthcare Safety Network (NHSN), Biovigilance Component Protocol. 2010. [cited 2012 Oct 30]. Available from: URL: http://www.cdc.gov/nhsn/PDFs/hemovigModuleProtocol- current.pdf
20. Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Cancer therapy evaluation program, common terminology criteria for adverse events (CTCAE) Version 3.0. 2006. [cited 2012 Oct 30]. Available from: URL: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf
21. Couban S, Carruthers J, Andreou P, Klama LN, Barr R, Kelton JG, Heddle NM,. Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion 2002; 42: 753-758.
22. Sanders RP, Maddirala SD, Geiger TL, Pounds S, Sandlund JT, Ribeiro RC, Pui CH, Howard SC,. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. Br J Haematol 2005; 130: 781-787.
23. Slonim AD, Joseph JG, Turenne WM, Sharangpani A, Luban NL,. Blood transfusions in children: a multi-institutional analysis of practices and complications. Transfusion 2008; 48: 73-80.
24. Gauvin F, Lacroix J, Robillard P, Lapointe H, Hume H,. Acute transfusion reactions in the pediatric intensive care unit. Transfusion 2006; 46: 1899-1908.
25. Fry JL, Arnold DM, Clase CM, Crowther MA, Holbrook AM, Traore AN, Warkentin TE, Heddle NM,. Transfusion premedication to prevent acute transfusion reactions: a retrospective observational study to assess current practices. Transfusion 2010; 50: 1722-1730.
26. Muylle L,. The role of cytokines in blood transfusion reactions. Blood Rev 1995; 9: 77-83.
27. Heddle NM,. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol 1999; 6: 420-426.
28. Domen RE, Hoeltge GA,. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 2003; 127: 316-320.
29. Vamvakas EC, Blajchman MA,. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113: 3406-3417.
30. Squires JE,. Risks of transfusion. South Med J 2011; 104: 762-769.
31. Karafin M, Fuller AK, Savage WJ, King KE, Ness PM, Tobian AA,. The impact of apheresis platelet manipulation on corrected count increment. Transfusion 2012; 52: 1221-1227.
32. Schoenfeld H, Muhm M, Doepfmer U, Exadaktylos A, Radtke H,. Platelet activity in washed platelet concentrates. Anesth Analg 2004; 99: 17-20.
33. de Wildt-Eggen J, Nauta S, Schrijver JG, van, Marwijk Kooy M, Bins M, van, Prooijen HC,. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000; 40: 398-403.
34. Kerkhoffs JL, Eikenboom JC, Schipperus MS, van, Wordragen-Vlaswinkel RJ, Brand R, Harvey MS, de, Vries RR, Barge R, van, Rhenen DJ, Brand A,. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006; 108: 3210-3215.
35. Herve F, Tardivel R, Semana G, Andreu G,. Large scale use of platelet additive solutions (PAS) reduces allergic type transfusion adverse events. Vox Sang 2007; 93 (Suppl S1): 267.
36. Oikawa S, Sasaki D, Kikuchi M, Sawamura Y, Itoh T,. Feasibility of a closed-system cell processor (ACP215) for automated preparation of washed platelet concentrates. Vox Sang 2012; 102: 110-115.